Outcomes according to fusion partner, induction regimen, and CR1 allogeneic transplantation in pediatric KMT2A-rearranged AML: the C-HUANAN-AML-15 multicenter cohort study
This multicenter cohort study of pediatric KMT2A-rearranged AML reveals that while outcomes vary significantly by fusion partner, the apparent superiority of the FLAG-IDA induction regimen over DAE was not confirmed after propensity-score matching, and no clear benefit of first complete remission allogeneic transplantation was observed in FLAG-IDA-treated patients with non-MLLT3 fusions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the bone marrow, where the body's blood cells are born, a specific type of cancer called acute myeloid leukemia can take hold. In children, this disease is driven by a genetic error where a gene named KMT2A breaks and fuses with another gene, creating a new, malfunctioning instruction set that tells blood cells to grow out of control. For decades, doctors have known that this specific genetic error does not affect every child in the same way; some children with this rearrangement do well, while others struggle. The medical community has long debated the best way to treat these children. Should they receive a very intense initial chemotherapy to try to wipe out the cancer immediately? And once the cancer disappears, is it necessary for every child to undergo a stem cell transplant from a donor, a procedure that carries significant risks and long-term side effects, or can some be cured with chemotherapy alone?
A large team of researchers across eleven hospitals in China set out to answer these questions by looking back at the records of 875 children treated between 2015 and 2023. They focused specifically on the 153 children whose leukemia was driven by the KMT2A gene rearrangement. The researchers wanted to see if the specific partner gene that fused with KMT2A mattered, whether one type of initial chemotherapy worked better than another, and if a stem cell transplant performed as soon as the cancer went into remission offered a survival advantage over continuing with chemotherapy.
The study revealed that the identity of the fusion partner is a critical factor in a child's outcome. The researchers found that children whose KMT2A gene fused with a partner called MLLT3 had significantly better results than those whose gene fused with any other partner. In fact, the children with the MLLT3 fusion fared almost as well as children with other types of leukemia that are considered low-risk, while those with other fusion partners faced higher risks of the disease returning. This suggests that treating all children with this genetic rearrangement as a single, high-risk group is too broad; the specific genetic makeup of the cancer matters deeply.
When the researchers compared the two main initial chemotherapy regimens, they found a complex picture. One regimen, which included a drug called fludarabine along with high doses of cytarabine, granulocyte colony-stimulating factor, and idarubicin, appeared to lead to better survival rates in the initial analysis. However, when the researchers carefully matched patients to account for differences in their starting health and age, the clear advantage of this intense regimen disappeared. The survival rates between the two groups became statistically similar, suggesting that while the more intense treatment might help some, it is not a guaranteed superior choice for everyone, and the extra intensity may not be worth the added strain on the body for all patients.
Perhaps the most significant finding concerned the use of stem cell transplants. Many doctors have assumed that children with this type of leukemia, especially those without the favorable MLLT3 fusion, should receive a transplant as soon as their cancer goes into remission to prevent it from coming back. The data from this study did not support that assumption. Among the children who received the intense initial chemotherapy, those who went on to have a stem cell transplant did not live longer or have lower rates of relapse than those who continued with chemotherapy consolidation alone. The researchers noted that their analysis could not prove that transplants are useless, as the decision to transplant was influenced by many factors, but the data showed no clear benefit to rushing into a transplant for these children.
Ultimately, the study paints a picture of a disease that is far more nuanced than previously thought. The outcome for a child with KMT2A-rearranged leukemia depends heavily on exactly which gene it fuses with and how well the cancer responds to the first round of treatment. The findings suggest that doctors should not treat all these children the same way. Instead, they should tailor their approach based on the specific genetic partner and the child's response to therapy, reserving the most aggressive interventions like stem cell transplants for those who truly need them, rather than applying them as a standard rule for everyone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.